IE910579A1 - Novel protein compositions - Google Patents

Novel protein compositions

Info

Publication number
IE910579A1
IE910579A1 IE057991A IE57991A IE910579A1 IE 910579 A1 IE910579 A1 IE 910579A1 IE 057991 A IE057991 A IE 057991A IE 57991 A IE57991 A IE 57991A IE 910579 A1 IE910579 A1 IE 910579A1
Authority
IE
Ireland
Prior art keywords
insulin
iii
ins
general formula
pharmaceutical composition
Prior art date
Application number
IE057991A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IE910579A1 publication Critical patent/IE910579A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
IE057991A 1990-02-21 1991-02-20 Novel protein compositions IE910579A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK045590A DK45590D0 (OSRAM) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
IE910579A1 true IE910579A1 (en) 1991-08-28

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
IE057991A IE910579A1 (en) 1990-02-21 1991-02-20 Novel protein compositions

Country Status (12)

Country Link
EP (1) EP0516704B1 (OSRAM)
JP (1) JPH05503940A (OSRAM)
AU (1) AU641991B2 (OSRAM)
CA (1) CA2075982A1 (OSRAM)
DE (1) DE69100626D1 (OSRAM)
DK (1) DK45590D0 (OSRAM)
HU (1) HUT63858A (OSRAM)
IE (1) IE910579A1 (OSRAM)
NZ (1) NZ237176A (OSRAM)
PT (1) PT96841A (OSRAM)
WO (1) WO1991012817A1 (OSRAM)
ZA (1) ZA911279B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
ES2402592T3 (es) 2003-08-05 2013-05-07 Novo Nordisk A/S Nuevos derivados de insulina
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
ES2601839T3 (es) 2006-09-22 2017-02-16 Novo Nordisk A/S Análogos de insulina resistentes a proteasas
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
JP6199956B2 (ja) 2012-04-11 2017-09-20 ノヴォ ノルディスク アー／エス インスリン製剤
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
WO2015052088A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3996679B1 (en) 2019-07-12 2023-09-06 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
DK45590D0 (OSRAM) 1990-02-21
ZA911279B (en) 1991-10-30
AU641991B2 (en) 1993-10-07
JPH05503940A (ja) 1993-06-24
CA2075982A1 (en) 1991-08-22
AU7337891A (en) 1991-09-18
DE69100626D1 (de) 1993-12-16
PT96841A (pt) 1991-11-29
HUT63858A (en) 1993-10-28
HU9202721D0 (en) 1992-12-28
NZ237176A (en) 1991-12-23
EP0516704A1 (en) 1992-12-09
WO1991012817A1 (en) 1991-09-05
EP0516704B1 (en) 1993-11-10

Similar Documents

Publication Publication Date Title
EP0516704B1 (en) Novel insulin compositions
AU2004251625B2 (en) Synthesis of high molecular weight iron-saccharidic complexes
US5456922A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
DE3880346T2 (de) Insulinderivate.
US4877778A (en) Method of enhancing lipophile transport using cyclodextrin derivatives
EP0855913B1 (en) Iron dextran formulations
KR890004687B1 (ko) 생물학적 활성 서방출성 조성물
CZ85790A3 (en) Novel preparations containing associates of hyaluronic acid, and process for preparing thereof
IE61340B1 (en) Stable interferon complexes
EP2943216B1 (en) Modified ace2 polypeptides
SA520420276B1 (ar) تركيبات صيدلية تحتوي على الأنسولين
CN118203658A (zh) 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法
EP2496213B1 (en) Pharmaceutical solution of non covalently bound albumin and acylated insulin
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
ZA200600846B (en) Novel insulin derivatives
PT93366A (pt) Processo para a preparacao de novas insulinas glicosiladas especificamente e decomposicoes farmaceuticas que as contem
CS209458B2 (en) Method of making the complex of the insuline salt with the protamine
Enriquez et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity
KR20100019979A (ko) 의약조성물
EP1308155B1 (en) Injectable solution containing a colloid of iron and shark cartilage-derived chondroitin sulfate
EP0013625B1 (en) Solubilized thymidine composition and method of producing same
EP1620072B1 (en) Zinc-containing sustained-release composition, its preparation, and method for producing the same
JP2716497B2 (ja) ヘモグロビン コンプレツクス
WO2007134595A2 (de) Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin
KR102022338B1 (ko) 당과 아미노산을 함유하는 안정한 수액제 조성물